SPRINT Trial Risk Stratification Calculator
- SPRINT Trial Risk Stratification: Explanation and Clinical Context
The SPRINT Trial (Systolic Blood Pressure Intervention Trial) risk stratification is a clinical tool designed to estimate the expected benefit and risk of intensive (<120 mmHg) versus standard (<140 mmHg) systolic blood pressure control in patients with hypertension.
It incorporates age, chronic kidney disease (CKD) status, and estimated 10-year ASCVD risk to classify patients into low, moderate, or high-risk categories.
High-risk patients, including those aged >75 years, with CKD, or with ASCVD risk >15%, derive the greatest absolute benefit from intensive blood pressure lowering but require close monitoring for adverse events such as hypotension, syncope, or acute kidney injury.
Moderate-risk patients may benefit from intensive control but with a lower absolute risk reduction. Low-risk patients have limited incremental benefit from intensive therapy.
This stratification informs individualized blood pressure targets and guides shared decision-making regarding intensity of antihypertensive therapy.
Reference:
Wright JT Jr, Williamson JD, Whelton PK, et al. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med. 2015;373:2103–2116. doi:10.1056/NEJMoa1511939
SPRINT Research Group. SPRINT Trial Design and Rationale. Hypertension. 2015;65:1224–1233.
Discussion
No discussions yet. Be the first to comment.
Create Note
Notes are stored privately on your device only. No login required. Nothing is uploaded or shared.